In vivo CRISPR base editing of ANGPTL3 shows durable lipid lowering, heading to trials
EricTopol · x · 2026-11-08
Eric Topol highlights a new Nature paper: in vivo CRISPR base editing of the ANGPTL3 gene achieved marked, durable lipid lowering in experimental models including non-human primates, moving toward clinical trials as a potential strategy for primary prevention of atherosclerosis.
More from Research
- Oxford researchers argue LLMs can't invent: 'Theory Is All You Need' paper on data vs. human cognition — alex_verem · 2026-11-08
- Researcher: Opus 5.5 ran pretraining scaling experiments unattended for a day — RylanSchaeffer · 2026-11-08
- Claude Opus 4.5 Hits 70.2% on SWE-bench While Wiping Context After Every Command — cephaloform · 2026-11-08
- François Fleuret asks: after a loss spike and recovery, is final loss worse, same, or better? — francoisfleuret · 2026-11-08
- Anders Sandberg: the real challenge is understanding where and why progress levels off — anderssandberg · 2026-11-08
- Z is Diophantine in Q proof slashes bounds: degree drops from 2↑↑7 to 4 — anderssandberg · 2026-11-08